Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?

Reinout van Crevel, Steven van de Vijver, David A J Moore

Tropical countries are experiencing a substantial rise in type 2 diabetes, which is often undiagnosed or poorly controlled. Since diabetes is a risk factor for many infectious diseases, this increase probably adds to the large infectious disease burden in tropical countries. We reviewed the literature to investigate the interface between diabetes and infections in tropical countries, including the WHO-defined neglected tropical diseases. Although solid data are sparse, patients with diabetes living in tropical countries most likely face increased risks of common and health-care-associated infections, as well as infected foot ulcers, which often lead to amputation. There is strong evidence that diabetes increases the severity of some endemic infections such as tuberculosis, melioidosis, and dengue virus infection. Some HIV and antiparasitic drugs might induce diabetes, whereas helminth infections appear to afford some protection against future diabetes. But there are no or very scarce data for most tropical infections and for possible biological mechanisms underlying associations with diabetes. The rise in diabetes and other non-communicable diseases puts a heavy toll on health systems in tropical countries. On the other hand, complications common to both diabetes and some tropical infections might provide an opportunity for shared services—for example, for eye health (trachoma and onchocerciasis), ulcer care (leprosy), or renal support (schistosomiasis). More research about the interaction of diabetes and infections in tropical countries is needed, and the infectious disease burden in these countries is another reason to step up global efforts to improve prevention and care for diabetes.

Introduction

Diabetes mellitus seems to increase the incidence and severity of many common infections, especially those caused by bacteria and fungi, and for some infections there is evidence that hyperglycaemia and poor glycaemic control correlate with infection risk and outcome. However, these findings are almost exclusively from studies performed in the resource-rich industrialised world, even though the global epidemic of type 2 diabetes is particularly thriving in low-income and middle-income countries. In this Review, we use “diabetes” when referring to type 2 diabetes. More than 80% of patients with diabetes live in low-income and middle-income countries, and 88% of deaths related to diabetes occur in these countries. According to the World Bank, more than 80 countries are classified as low income and lower-middle income, but in this Review we will use the term “tropical countries” to refer to a bigger number of countries (149 countries according to WHO) with tropical and subtropical conditions, many of which would be classified as upper-middle income (eg, Botswana, China, Colombia, Malaysia, Peru, and Thailand) or even high income (eg, Argentina and Venezuela). The number of patients with diabetes is projected to increase by 55% globally in the next 20 years, but this value disguises how the brunt of the increase will be borne by tropical countries, with predicted increases of 109% in Africa, 96% in the Middle East and north Africa, and 71% in southeast Asia. Studies suggest that these estimates could even be too conservative. For instance, in China, there are now an estimated 114 million people with diabetes, with a national prevalence of 11.6% in 2010 compared with 5.5% in 1980. The proportion of diabetes that is undiagnosed or poorly controlled is also much higher in tropical countries than in better-resourced industrialised countries.1

In this Review, we first briefly discuss the risk from diabetes for infectious diseases in general, referring to potential underlying mechanisms. We then discuss what factors could contribute to a higher burden of diabetes-associated infections in tropical countries, specifically referring to diabetic foot and tropical diabetic hand syndrome. We briefly review what is known about diabetes and tuberculosis (reviewed previously) and HIV, and discuss what is known about diabetes with respect to malaria, emerging viral infections, and the so-called neglected tropical diseases (NTDs). Finally, we explore the implications of the increasing importance of diabetes-associated infections for health systems in tropical countries. In the absence of a good evidence base for many of the key questions, we end with some of the priorities for future research and action.

Diabetes mellitus and infectious diseases

Infections are a common cause of morbidity and mortality in patients with diabetes, with important health and socioeconomic implications. Some relatively rare infections—such as rhinocerebral mucormycosis, Fournier’s gangrene, and Klebsiella pneumoniae liver abscess—occur almost exclusively in patients with diabetes. Mucocutaneous and invasive fungal infections, mostly caused by Candida species, are also more common in individuals with diabetes; as are common infections including bacterial pneumonia, urinary tract infections, bloodstream infections, skin infections,
soft-tissue infections, and eye infections. Infections are not only more common in people with diabetes but can also be more severe than in those without diabetes. For instance, observational studies have shown diabetes to be associated with both increased rate of hospital admission and increased time spent in hospital because of infections; increased rates of admission to intensive care units; increased mortality for pneumonia, bloodstream infections, and influenza; increased rates of amputation and death for necrotising limb infections; and greatly increased rates of endogenous endophthalmitis among patients with fungaemia or bacteraemia. Diabetes might also affect antibiotic treatment; it has been associated with increased antimicrobial drug resistance—e.g., among Enterobacteriaceae—whereas impaired kidney function and liver steatosis associated with diabetes increase the risk of antimicrobial drug toxicity. Finally, preventive vaccination could be less effective in people with diabetes, as has been shown for influenza vaccination.

Several mechanisms contribute to the increased frequency and severity of infections in people with diabetes. Firstly, diabetes is associated with decreased host immunity to infections. Diabetic neuropathy, macroangiopathy, and microangiopathy contribute to increased rates of skin lesions and poor wound healing, and patients with diabetes have been shown to have decreased functioning of immune cells, including neutrophils, macrophages, T cells, and antibody-producing B cells. Other factors that could impair immune responses in diabetes include obesity, vitamin D deficiency, oxidative stress, and possibly diabetes drugs. People living with diabetes have an increased rate of Staphylococcus aureus carriage, and glycosuria predisposes individuals to outgrowth of uropathogens. Finally, patients with diabetes have an increased rate of health-care-associated infections because of more frequent attendance at health-care facilities, hospitalisation, and instrumentation during medical procedures.

As reviewed in The Lancet Diabetes and Endocrinology, epidemiological studies have linked more profound hyperglycaemia with increased infection rates and mortality, increased risk of hospitalisation from pneumonia, some bloodstream infections, and urinary tract infections.

**Diabetes and infections in tropical countries**

For most infections associated with diabetes there is a striking paucity of comparative population-level data from tropical countries as compared with high-income countries, in terms of diabetes prevalence, infection rates, and risk estimates for infections in patients with diabetes. A major factor contributing to this knowledge gap is uncertainty about the reliability of case ascertainment because of weak diagnostic services (table 1). Also, reduced access to health services means that hospital-derived data miss an important proportion of cases, and might over-represent severe diseases. Although infections represent a larger proportion of hospitalisations in tropical countries than in high-income countries, this difference reflects casemix and is not a useful surrogate of comparative incidence. Similarly missing are data on the proportion of these common infections that are attributed to diabetes in tropical countries, or on differences in severity due to diabetes.

Even though reliable data for most infections are unavailable, it is highly likely that patients with diabetes in tropical countries are at increased risk for common bacterial and other infections for several reasons. Firstly, diabetes is more likely to be undiagnosed and therefore unmanaged in resource-constrained tropical settings than in wealthier countries, and even if the condition is diagnosed, it is more likely to be associated with poor glycaemic control. Unavailability, insecure supply, or high costs of diabetes medication, and issues related to storage and use of insulin, all compromise glycaemic control in many resource-constrained settings.

Similarly, healthy diet and lifestyle are relatively low priorities for people living in poverty or under difficult conditions in tropical countries, and health education...
and self-management of diabetes are challenging. Additionally, the number of health providers available to properly educate, treat, and monitor diabetes is low in such settings. In sub-Saharan Africa, for instance, there were an estimated 16 physicians per 100,000 people in 2011 (17 times less than in the USA and UK) while for most African countries, large numbers of physicians continue to emigrate.34

Another contributing factor is reduced access to diagnostic and therapeutic services, or to good-quality care for infections (table 1). This will further lead to failing treatment, recurrent infections, and development of antimicrobial drug resistance. Hospitals in low-resource settings are often a source of infection, with risks of health-care-associated infection substantially higher than reported in industrialised countries.29 Although evidence is inadequate, it seems plausible that diabetes is over-represented among hospitalised patients in such settings. For instance, diabetic foot complications are the main cause of prolonged hospital stays for patients with diabetes in tropical countries, which could lead to high rates of drug resistance, especially in the case of treatment for diabetic foot ulcers. For example, in a hospital-based study of diabetes patients in Algeria, 86% of Staphylococcus aureus were meticillin resistant, and 60–80% of Escherichia coli and Klebsiella isolates from diabetic foot infections were multidrug resistant.35 Also, transmission of viral hepatitis and HIV in low-resource settings has been attributed to the shared use of glucose meters in health institutes.36 It should be noted that diabetes is not well captured by considering it as a single disease entity, and the risks faced by people with diabetes and the care provided is hugely variable between different countries, between rural and urban settings, and between primary health clinics and hospitals. However, good epidemiological data exploring the importance of these and other such factors are extremely rare (table 1).

**Diabetic foot infections and tropical diabetic hand syndrome**

In tropical countries, diabetic foot problems are a common complication of diabetes and an important cause of morbidity and mortality. For instance, from a study in Ethiopia showed that diabetic foot ulcers accounted for 39% of admissions of patients with diabetes.27 Reports from Africa and Asia suggest that neuropathy rather than peripheral vascular disease underlies diabetic foot problems, although this situation might be changing because of an increase in cardiovascular disease and its risk factors.38–40 Inadequate footwear and walking barefoot can contribute to neuropathic foot ulcers in tropical countries. Infection is usually a consequence rather than a cause of foot ulcers, but concomitant infections cause delays in wound healing, and in the absence of proper management, infected diabetic foot ulcers could progress to systemic infection, gangrene, limb loss, and death.40 As a result, diabetic foot infections are cited as a major cause of prolonged hospital stays, cause of amputation, and mortality in resource-constrained settings.40 As one Indian doctor wrote, “the severely infected foot is the hallmark of the diabetic foot commonly seen in India”,40 and this observation is probably true for many tropical countries.

Tropical diabetic hand syndrome is a more-aggressive, upper limb version of the diabetic foot and has been reported in Africa and Asia.41–43 So far, only small case series have been published, but the syndrome seems to range from localised cellulitis and swelling to ulceration of the hands, sepsis, and gangrene. It usually follows minor or unrecognised trauma and can lead to amputation. The prevalence of diabetic hand syndrome in tropical countries is due to a combination of factors, including rapid spread of infection in the hand, delayed access to health care, and poor glycaemic control.

Amputation is a marker not only of disease severity, but also of disease management and quality of health services. Although reliable epidemiological data are scarce, it appears that amputation rates for diabetic foot are much higher in tropical countries compared with industrialised countries.4 For instance, amputation was performed in 15% of patients in hospital with foot ulcers in a study in Pakistan,41 and in 33% of patients with foot ulcers in Tanzania.4 In India, although precise data are absent, it is estimated that 45,000 legs are amputated yearly, with approximately 75% resulting from infected neuropathic feet.42 Scarcity of knowledge, patients’ delay in seeking treatment, paucity of foot care, and unavailability of suitable facilities and trained personnel challenge the implementation of multidisciplinary programmes that are used in industrialised settings.43

The success of specific projects, such as the “Step by Step” Diabetic Foot Project in Tanzania, suggests that there might be opportunities for reducing morbidity and mortality even when resources are limited.44

**Mucormycosis**

Mucormycosis is a fungal infection that is noteworthy for being particularly aggressive in patients with diabetes. It is caused by zygomycetes and is characterised by rapidly progressive tissue necrosis. It usually presents as rhino-orbital-cerebral disease, especially in patients with diabetes.45 However, it can also present as pulmonary, cutaneous, gastrointestinal, or disseminated disease. In developed countries incidence of mucormycosis is increasing. The infection is usually seen in immunocompromised patients, especially because widely used azole antifungal drugs are inactive against mucormycosis.46 However, in developing countries, especially India, the number of zygomycosis cases seems to be increasing because of increasing numbers of cases in patients with uncontrolled or unrecognised diabetes.47–52 In a single tertiary care centre in India, the number of cases witnessed in the past 25 years increased approximately six times;53 and a case series showed that
131 (74%) of 178 patients had mucormycosis associated with diabetes\(^*\) (compared with 86 [16%] of 531 patients in France\(^*\)) and a quarter of patients did not know that they had diabetes. Mortality is high, especially in low-resource settings where use of amphotericin B, appropriate surgery with debridement of necrotic tissue, and correction of uncontrolled diabetes might be more difficult. As a result of diabetes, other invasive mould infections, especially those caused by Aspergillus flavus, might also be on the rise in tropical countries.\(^*\)

**Effect of diabetes mellitus on tuberculosis, HIV, and malaria**

In addition to the universal presence of common bacterial and other infections, tropical countries are disproportionately affected by the so-called big three: HIV, tuberculosis, and malaria. The interaction between diabetes and tuberculosis has been reviewed extensively.\(^*\)\(^*\) People with diabetes are at three times increased risk of developing active tuberculosis compared with people who do not have diabetes,\(^*\) especially those with poor glycaemic control who have an even higher risk.\(^*\) Diabetes is also associated with increased rates of death, treatment failure, and recurrent disease.\(^*\) As such, the rise in diabetes prevalence in tuberculosis-endemic countries is seen as a major threat to further control of tuberculosis.

With regard to HIV, of the few studies done in tropical countries, a study in Tanzania found that the rate of glucose metabolism disorders (as measured by oral glucose tolerance test) among HIV patients on antiretroviral therapy was six times higher than that in HIV-negative patients matched for age and obesity.\(^*\)

Studies in Ethiopia and South Africa have found that long duration of HIV treatment is associated with increased incidence of diabetes.\(^*\)\(^*\) This effect might be explained by mitochondrial toxicity associated with older anti-HIV drugs (zidovudine, stavudine, didanosine, and saquinavir)\(^*\)\(^*\) that are still prescribed in some tropical countries, as well as newer drugs like efavirenz, as shown in a very large cohort in South Africa.\(^*\) Additionally, in part due to the successful roll-out of HIV treatment in Africa, there are increasing numbers of older people at increased risk of developing diabetes.\(^*\) Concurrent hepatitis C virus infection has also been linked with diabetes in HIV-infected patients, although data are conflicting.\(^*\)\(^*\) and dialysis for end-stage renal disease in diabetes constitutes a risk for transmission of blood-borne viruses, including HIV, in tropical countries.\(^*\)\(^*\)

Much less is known about the association between diabetes and malaria, which affects approximately 200 million individuals worldwide each year.\(^*\) We identified only one study examining a possible association. In a large case-control study in Ghana, asymptomatic malaria parasitaemia was more common in people with diabetes compared with people without diabetes (17·4% vs 11·3%), and was higher in people with poor glycaemic control than in those with adequate glycaemic control.\(^*\) Malaria is more common in pregnancy than in age-matched non-pregnant women, and is associated with anaemia, increased maternal mortality, abortion, preterm delivery, and neonatal deaths.\(^*\) If diabetes increases malaria parasitaemia, as the study from Ghana suggests, gestational diabetes might increase the incidence, morbidity, and mortality of pregnancy-associated malaria. Such an association would be relevant, especially in light of the rising global incidence of gestational diabetes.\(^*\) However, to our knowledge, this association has not been studied to date.

**Diabetes and neglected tropical diseases**

People living in tropical countries are affected by a range of specific tropical diseases, such as helminth, parasitic, mycobacterial, and viral infections. WHO has compiled a list of 18 important NTDs (table 2)—but many other important conditions have not been included, at least eight of which were included in the Global Burden of Disease Study in 2010.\(^*\) NTDs have a lower mortality than HIV, tuberculosis, and malaria, but collectively NTD morbidity adds up to an estimated 48 million disability-adjusted life-years, similar to that for tuberculosis.\(^*\) Here we review what is known about NTDs in relation to diabetes, although data are scarce. Diabetes could increase the risk of some NTDs, whereas others appear to afford some protection against diabetes. Additionally, treatment of some NTDs could contribute to the development of diabetes or interfere with glycaemic control.

**Bacterial infections**

Regarding bacterial infections, diabetes might affect the incidence and phenotype of leprosy. In India, diabetes was identified in 14·2% of patients with leprosy in Uttar Pradesh, compared with only 2% in people without leprosy.\(^*\) Diabetes prevalence was strikingly different when disaggregated by disease phenotype: 19·3% in lepromatous leprosy and 6·4% in tuberculoid leprosy,\(^*\) a finding that was replicated in a smaller study in Kuwait in 2012.\(^*\) Diabetes might also interact with leprosy treatment. In India, ulcer management was more complex and consequently treatment in hospital was longer in patients with diabetes than in those without diabetes,\(^*\) in addition prolonged use of steroids for leprosy reversal reactions might induce diabetes.\(^*\)

Melioidosis, although not included in the WHO list of NTDs, is a tropical disease that has long been recognised for its association with diabetes. It is a severe infection that can manifest as sepsis, pneumonia, or abscesses (figure). It is caused by the Gram-negative bacterium, Burkholderia pseudomallei, and is particularly well recognised in southeast Asia and northern Australia. Precise risk estimates are scarce, but 40–60% of patients with melioidosis in different studies also have diabetes.\(^*\)\(^*\) These epidemiological data are supported...
by results from numerous immunological studies showing decreased *B pseudomallei* phagocytosis and killing, and altered cytokine responses by neutrophils and monocytes from people with diabetes.23,102,103 Diabetes medication might also affect susceptibility and presentation of melioidosis. The use of sulfonylurea derivatives was strongly associated with decreased proinflammatory cytokine responses and increased severity of melioidosis in a study in Singapore,28 although the opposite was found in a large cohort in Thailand.104 There are no published data on an interaction with diabetes for other bacterial infections such as Buruli ulcer, a destructive skin and subcutaneous tissue disease caused by *Mycobacterium ulcerans*, despite the well-established association of diabetes with disease due to *Mycobacterium tuberculosis*. The same is true for yaws, the most common of the endemic treponemal infections, which presents as skin and bone disease and is the subject of a renewed WHO-led initiative aimed at elimination, as well as for trachoma, an eye infection caused by *Chlamydia trachomatis*.

### Viral infections

Viral infections constitute a growing global health problem. They include infections with dengue virus, which is included in the list of NTDs; other arboviruses transmitted by mosquitoes; respiratory viral infections, including severe acute respiratory syndrome, Middle East respiratory syndrome, and infection with certain influenza strains; and haemorrhagic fever viral infections, such as Ebola virus disease. Regarding a possible relation with diabetes, most is known about dengue. Dengue is a mosquito-borne viral infection that has had an enormous geographical expansion, with an estimated 390 million cases in 2012.105 Epidemiological data have shown that diabetes is associated with increased severity of dengue-induced thrombocytopenia,72 a two-to-three times increased risk of severe dengue (previously known as dengue shock syndrome and dengue haemorrhagic fever),73–76 an independent five times increased risk of acute kidney injury,77 and increased admission to the intensive care unit.78 For infection with West Nile virus—an arbovirus that has

| Articles identified | Link with diabetes | Common end-organ morbidity? | Shared health system needed? | Comments |
|---------------------|--------------------|-----------------------------|-----------------------------|----------|
| Buruli ulcer        | 0                  | No data                     | Tissue viability services   | Mycobacterial disease |
| Chagas disease      | 14                 | Hyperglycaemia more common in Chagas cardiomyopathy than in controls15 | Cardiomyopathy and gastrointestinal motility | Cardiology | Parasite control diminished and mortality increased in diabetic mice |
| Dengue              | 11                 | Diabetes increases risk of severe dengue and exacerbates thrombocytopenia72–74 | No                         | No       |
| Chikungunya         | 1                  | No data                     | No                          | No       |
| Dracunculiasis      | 3                  | No data                     | No                          | No       |
| Echinococcosis      | 1                  | No data                     | No                          | No       |
| Yaws                | 23†                | No data                     | No                          | No       |
| Food-borne trematodases | 2‡               | No data                     | No                          | No       |
| Human African trypanosomiasis | 21          | No data                     | No                          | Only murine studies |
| Leshmaniasis        | 40                 | Only sporadic case reports of modified phenotype | No                          | No       |
| Leprosy             | 99                 | Diabetes prevalence higher in lepromatous than tuberculoid16 | Neuropathic ulcers and blindness | Tissue viability services and eye health services | Steroid-induced diabetes in therapy of leprosy reactions |
| Lymphatic filariasis| 2                  | Lymphatic filariasis prevalence reduced in diabetes patients16 | No                         | Tissue viability services | Reduced proinflammatory cytokines in lymphatic filariasis |
| Onchocerciasis      | 4                  | No data                     | Blindness                   | Eye health services | |
| Rabies              | 3                  | No data                     | No                          | No       |
| Schistosomiasis     | 31                 | Diabetes inversely associated with previous schistosomiasis in China;66 attenuated schistosomiasis phenotype in diabetes (decreased egg counts and reduced granulomas) | Renal impairment            | No       |
| Soil-transmitted helminthiases | 57            | Soil-transmitted helminthiases inversely associated with diabetes (Indonesia);66 previous strongyloides inversely associated with diabetes (Australia)66 | No                         | No       |
| Taeniasis or cysticercosis | 2                  | --                          | No                          | No       |
| Trachoma            | 15                 | --                          | Blindness                   | Eye health services | |

IDDM=insulin-dependent diabetes. *Tissue viability services encompasses foot care services.123 articles were identified using MeSH terms "diabetes mellitus" AND ("yaws" OR "treponem*") and almost all results related to periodontal disease.1 MeSH terms used were "diabetes mellitus" AND ("clonorchis" OR "opisthorchis" OR "fasciola" OR "paragonimus").

Table 2: Key observations on diabetes and neglected tropical diseases from published literature
some uncertainty regarding a possible effect of diabetes on leishmaniasis, a disease caused by a sandfly-borne kinetoplastid parasite. Leishmaniasis is phylogeographically determined, with South American species mostly causing cutaneous disease and species in Africa and Eurasia causing cutaneous as well as visceral disease. Isolated case reports suggest that diabetes can affect the phenotype of cutaneous disease, with unusually ulcerative Leishmania major lesions occurring in patients with diabetes in Morocco, and more numerous lesions reported in diabetes patients in France and Italy from Leishmania infantum compared with those without diabetes. Subclinical (or perhaps prepatent) leishmanial infection is increasingly recognised, but whether diabetes is a risk factor for progression to clinical disease has not been reported. In a small series in Saudi Arabia, six of 13 patients with presumed recrudescent disease were noted to have diabetes. Finally, the diabetogenic side-effect of pentamidine, a key drug for leishmaniasis, is well recognised, often necessitating the use of insulin.

Chagas disease, or American trypanosomiasis, which is caused by the parasite Trypanosoma cruzi, leads to end-organ damage to the heart and gastrointestinal tract in around a third of infected patients. In a single study, diabetes and hyperglycaemia were more common in patients with Chagas cardiomyopathy than in patients with Chagas but without cardiomyopathy and healthy people. This study supports the hypothesis that the reduced parasympathetic activity caused by T cruzi leads to relative sympathetic hyperactivity, and is consistent with a small study by the same group implicating T cruzi infection in subtle intrapancreatic denervation changes. Whether these data really implicate T cruzi in the development of impaired glucose tolerance or whether hyperglycaemia predisposes patients to more symptomatic infection remains unclear. In a mouse model of diabetes, hyperglycaemia was associated with markedly reduced control of experimental T cruzi parasitaemia and increased mortality. For African trypanosomiasis—a parasitic disease spread by tsetse flies—no link with diabetes has been published, although murine infection with Trypanosoma brucei rhodesiense (which causes East African trypanosomiasis) appeared to offer some protection against inducible diabetes.

Helminth infections

Some helminth NTDs are associated with reduced diabetes prevalence. In a cross-sectional study in Indonesia, infection with the soil-transmitted helminths ascaris, trichuris, hookworm, or strongyloides was inversely correlated with insulin resistance, and this association was not explained by differences in BMI. Similarly, serological evidence of previous strongyloides infection was independently associated with a 60% lower prevalence of type 2 diabetes in an Indigenous Australian population with high rates of both, although the opposite was found in a much smaller study in Brazil. Strongyloides hyperinfection, a disseminated manifestation of the disease with a high parasite burden that mainly occurs in immunocompromised individuals, has been reported in patients with diabetes, although these reports provide insufficient evidence of increased susceptibility.

Lymphatic filariasis, a filarial nematode disease caused by Wuchereria bancrofti or Brugia malayi, might also protect against diabetes. The disease accounts for...
substantial disability due to chronic—sometimes gross—lower limb lymphoedema, particularly in Africa and Asia. In Chennai, India, prevalence of lymphatic filariasis was inversely correlated with type 1 diabetes,93 with a reduction in proinflammatory cytokines proposed as a possible explanation for a protective effect.94

Schistosomiasis or bilharzia, a helminth infection transmitted by freshwater snails, might also protect against diabetes. In mice, exposure to schistosomal egg antigen reduces the risk of insulin-dependent diabetes, possibly through induction of adipose tissue M2 macrophages and expansion of regulatory T cells,87–90 both of which might provide a protective effect against diabetes. In a large cross-sectional study in China (n=9359), previous schistosomal infection was 50% less common among people with diabetes than in people without diabetes.86 No published data were found on a possible relation between other helminth infections and diabetes. For instance, no clinical data have been published for cysticercosis, a major cause of epilepsy caused by the larval stage of the pork tapeworm *Taenia solium*, although in mice pre-existing *Taenia crassiceps* infection attenuated the diabetogenic effect of streptozotocin.84 No human data have been published for food-borne helminths such as *Fasciola, Clonorchis, Opisthorchis* and *Paragonimus*, but the onset of diabetes in non-obese diabetic mice can be prevented through early exposure to secreted or excreted antigens of *Fasciola hepatica*.95 There are also no data for echinococcosis, also known as hydatid disease, a parasitic disease caused by a dog tapeworm, aside from a single case report of hydatid disease of the pancreas resulting in diabetes.121 The same is true for onchocerciasis (river blindness) and for dracunculiasis (guinea worm disease), the latter of which is now mainly limited to Sudan, and is acquired through ingestion of water fleas infected with worm larvae. Overall, however, data seem to suggest that some helminth infections might protect against diabetes. As such, more research is needed to see whether decreasing rates of helminth infections or deliberate global deworming through mass drug administration programmes is subsequently accompanied by an increase in the prevalence of diabetes.122

**Implications for health services**

Health services in tropical countries are affected by a double burden of disease: infectious and non-communicable diseases.123 There is an estimated shortage of more than 4 million health workers globally,124 combined with a genetic and epigenetic mismatch of their inhabitants with new (and more affluent) environments.125 Therefore, it is essential for international organisations to take action and to partner with fragile services in tropical countries to deal with both infectious diseases and non-communicable diseases. Such actions include integration of surveillance, prevention, and care for different diseases; innovations to lessen the burden for health services; task shifting and self-management of diseases; and more funding to strengthen current health systems (table 3).

**Primary prevention**

At the level of primary prevention, well-distributed health education for infectious diseases, such as handwashing and hygiene in schools and other public spaces, could be extended to messages related to prevention of non-communicable diseases such as diabetes. Counselling and education on behavioural change for prevention of chronic diseases tend not to have strong effects in western settings,126 but these interventions could have

---

**Integrated approach to disease prediction and control**

| Integration of care | Innovative model for incentives to prevent infectious and non-communicable diseases79 |
|---------------------|---------------------------------------------------------------------------------------|
| Prevention          | Screening HIV patients for cardiovascular risk factors130                           |
| Screening           | Integration of care for diabetes and tuberculosis4                                 |
| Care                |                                                                                                                                 |
| Technical solutions | Smartphone applications to replace laboratory immunopassays61                          |
| Simplified diagnostics | Use of new collective methods and digital images52                                      |
| Disease monitoring  | Text messages to increase adherence to antiretroviral therapies120                    |
| Electronic health   | Simplify chronic treatment using depot medication70                                     |
| Depot medication    |                                                                                                                                 |
| Health service delivery | Diabetes management shifted from senior health workers towards nurses128            |
| Task-shifting       | Peer support for diabetes and hypertension patients129                                 |
| Peer support        | Health prevention and treatment in work environments134                                |
| Work-based support  |                                                                                                                                 |
| Funding             | Commitment to UN declaration to mobilise funds for medication61                       |
| Government          | Scholarships for studies in global health with preference for combining communicable and non-communicable diseases61 |
| Research            |                                                                                                                                 |

---

**Table 3: Suggested approaches to strengthen services in tropical countries to deal with communicable and non-communicable diseases**
more effect in tropical countries where awareness is low and motivation often becomes high once people are well informed.\textsuperscript{43} These health education programmes might even be linked with health surveillance in factories and other work environments where good hygiene and health among employees is increasingly supported for economic reasons.\textsuperscript{119,135} Besides healthy behaviour and awareness, there should also be increased emphasis on coordination of combined screening and diagnosis of infectious and non-communicable diseases, both in health-care settings and community and work spaces.\textsuperscript{145}

**Strengthening chronic care**

Growing awareness and screening of patients at high risk for developing diabetes would lead to an increase of patients attending health-care services, where treatment and monitoring should be strengthened and better integrated. This approach has shown to be effective, for instance, in a programme addressing diabetes and HIV in African countries.\textsuperscript{144} Treatment adherence—which is often low in tropical countries, for infectious and non-communicable diseases—should be emphasised in the pathway of care. New technologies such as electronic health and mobile health have shown to be effective in this respect, for instance, in maintaining adherence to antiretroviral therapy,\textsuperscript{115} but also in maintaining a healthy diet\textsuperscript{142} and diabetes prevention,\textsuperscript{144} as shown in randomised clinical trials in Latin America and India, respectively. New technologies might also alleviate the burden on health services by simplifying diabetes diagnosis, these developments are underway for infectious diseases for example, through smartphone applications that replace laboratory-quality immunoassays,\textsuperscript{131} through innovative mosquito traps and digital images that can replace skilled entomologists in monitoring the spread of malaria-carrying mosquitoes,\textsuperscript{132} or with depot medication that simplifies chronic treatment, such as is being developed for HIV treatment.\textsuperscript{144} As far as we are aware, there are no nascent technologies for diabetes diagnosis or monitoring.

Finally, practical solutions should be implemented to diminish the increasing burden of diabetes on health services. Solutions include shifting care of diabetes from senior health-care workers towards nurses,\textsuperscript{125,126} involvement of community health-care workers,\textsuperscript{149} and introduction of peer support for patients with diabetes in low-resource settings,\textsuperscript{127,128} all of which have been shown to be effective in the management of diabetes or cardiovascular risk. It should be noted that integration of care for NTDs with other services is likely to be more challenging than, for instance, for HIV. NTDs include a whole range of infectious diseases, some rare, some lacking awareness, and many with a scarcity of good diagnostic tools or effective treatment options.

**Overlapping morbidity**

The morbidity arising from some NTDs overlaps with that of diabetes. The two most important NTDs that cause blindness are trachoma and onchocerciasis. Trachoma results from chronic inflammation mediated by *C trachomatis*. Although there appear to be no biological associations, the key interaction with diabetes is the relative demand for eye health services.\textsuperscript{130} In 2010, 1.4% of global blindness (total 32.4 million people) was attributable to trachoma, and 2.4% to diabetic retinopathy. Cataract, which is frequently a complication of diabetes, was the cause of a third of all blindness. Onchocerciasis results from ocular inflammation caused by the microfilariae of the nematode *Onchocerca volvulus*. No interaction with diabetes has been reported, but as with trachoma, onchocerciasis represents a competing demand on eye health services in endemic regions. A more optimistic view would be that it represents an opportunity for added value from service provision. The global map of trachoma is currently being populated by data; it is hoped that efforts at control through the SAFE strategy will start to shrink areas of hyperendemicity. Onchocerciasis prevalence is falling as intermittent mass drug therapy with ivermectin is rolled out in sub-Saharan Africa, and the last remaining areas in Latin America are close to achieving elimination.

End-stage kidney disease provides another example of potential for sharing of health services. In tropical countries, poorly managed and recurrent common urinary tract infections, and obstructive uropathy due to *Schistosoma haematobium* contribute, like diabetes, to the burden of end-stage renal failure that is poorly served in resource-constrained countries.\textsuperscript{129,130}

Leprosy and diabetes share several morbidity sequelae; both diseases feature in the differential diagnosis of peripheral neuropathy and mononeuritis multiplex, and are among the causes of Charcot joint (neuropathic arthropathy). As such, there is potential for overlap of use of clinical services related to peripheral neuropathy and neuropathic foot ulcers, although the additional vascular compromise seen in the diabetic foot is not a feature of leprosy neuropathic ulcers. Surveillance data for eye, kidney, and neuropathic complications of NTDs and diabetes in tropical countries are scarce. As a result, it is impossible to estimate the number of diagnosed and undiagnosed patients who would benefit from integrated services. What seems obvious, though, is that the projected global growth of diabetes will greatly increase the need and costs of preventive and therapeutic services. Brazil for instance, witnessed a 20% growth in diabetes between 2006 and 2010, with an estimated annual direct cost of diabetes of almost US$4 billion.\textsuperscript{130} Diabetes-associated infections are likely to be a major factor in these costs.

**Conclusions**

Several conclusions can be made with respect to the relation between diabetes and infectious diseases in tropical countries. First, the global diabetes epidemic disproportionally affects tropical countries, where
chronic care, glycaemic control, and wound and foot care can be very challenging. Diabetes increases incidence and severity, and affects treatment and outcome of a large number of infectious diseases, including many—such as tuberculosis and dengue—that have the highest burden in tropical countries. This incidence puts a heavy burden on health services that are often already overstretched. Second, health-care-associated infections and antimicrobial drug resistance are a major problem for patients with diabetes in tropical countries. Third, while some helminth infections might afford protection against diabetes, diabetes might increase the risk or severity of other helminth infections, although data are scarce. Fourth, there is a general scarcity of epidemiological, clinical, and health systems research addressing the interaction of diabetes and infectious diseases in tropical countries except for tuberculosis and melioidosis, and there are very few data on underlying mechanisms or the effect of diabetes medication. As such, there is an urgent need for more research to address all these issues, and for efforts to better link or integrate care for communicable and non-communicable diseases. And of course, in light of the dramatic rise in diabetes prevalence in tropical countries, the interaction between diabetes and infectious diseases is yet another reason to improve prevention and management of diabetes in high-burden tropical countries.

Contributors

RvC and DAJM were responsible for additional literature searches and the section on NTDs. All authors contributed to the final draft.

Declaration of interests

We declare no competing interests.

Acknowledgments

RvC and DAJM are supported by the TANDEM project on tuberculosis and diabetes, which is funded by the European Union’s Seventh Framework Programme (FP7/2007–2013) under grant agreement number 305279.

References

1. Rizza RA, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol 2014; 2: 760–53.
2. Peleg AY, Weeraratna T, McCarthy JS, Davis TME. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2006; 23: 3–13.
3. International Diabetes Federation, IDF diabetes, 7 edn. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org (accessed July 21, 2016).
4. Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol 2014; 2: 980–91.
5. Lonnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014; 2: 730–39.
6. Odono A, Houwen RM, White RG, Linnroth K. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol 2014; 2: 754–64.
7. Hotze PJ, Alvarez M, Basáñez M-G, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 2014; 8: e2865.
8. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–71.
9. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743–800.
10. Singh V, Sharma B, Sen R, Agrawal S, Bhagol A, Bali R. Rhinocerebral mucormycosis: a diagnostic challenge and therapeutic dilemma in immunocompetent host. J Oral Maxillofac Surg 2012; 70: 1369–75.
11. Suu LK, Yeh K-M, Lin J-C, Fung C-P, Chang F-Y. Klebsiella pneumoniae liver abscesses: a new invasive syndrome. Lancet Infect Dis 2012; 12: 881–87.
12. Hirji I, Gao Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications 2012; 26: 513–16.
13. Kornnum JB, Thomsen RW, Riis A, Lervang H-H, Schambheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007; 30: 2251–57.
14. Thomsen RW, Riis AH, Kjeldsen S, Schambheyder HC. Impact of diabetes and poor glycaemic control on risk of bacteremia with haemolytic streptococci groups A, B, and G. J Infect 2011; 63: 8–16.
15. Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Sørensen HT, Schambheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2006; 29: 79–76.
16. Grijalva CG, Zhu Y, Williams DJ, et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA 2015; 314: 1488–97.
17. Uehara K, Yasunaga H, Morizaki Y, Horiguchi H, Fushimi K, Tanaka S. Necrotising soft-tissue infections of the upper limb: risk factors for amputation and death. Bone Joint J 2014; 96-B: 1530–34.
18. Vaziri K, Pershing S, Albini TA, Moslehfighi DM, Moslehfighi AA. Risk factors predictive of endogenous endophthalmitis among hospitalized patients with hematogenous infections in the United States. Am J Ophthalmol 2015; 159: 498–504.
19 Seraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae—a case-control study in a low prevalence country. PLoS One 2013; 8: e69581.

20 Wu Y-H, Chen P-L, Hung Y-P, Ko W-C. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. J Microbiol Immunol Infect 2014; 47: 197–203.

21 Guh AV, Bulens SN, Ma Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US Communities, 2012–2013. JAMA 2015; 314: 1679–87.

22 Castilla J, Godoy P, Domínguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis 2013; 57: 167–75.

23 Gan Y-H. Host susceptibility factors to bacterial infections in type 2 diabetes. PLoS Pathog 2013; 9: e1003794.

24 Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology 2015; 144: 171–83.

25 Ronacher K, Isosthen SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff THM. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev 2015; 264: 121–37.

26 Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012; 16 (suppl 1): S27–36.

27 Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Clin Transl Med 2014; 6: e236a159.

28 Liu X, Foo G, Lim WP, et al. Sulphonylurea usage in melioidosis is associated with severe disease and suppressed immune response. PLoS Negl Trop Dis 2014; 8: e2795.

29 Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 148–58.

30 Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol 2016; 4: 144–46.

31 Manne-Goehler J, Atun R, Stokes A, et al. Unmet need for diabetes care in sub-Saharan Africa: individual pooled analysis in 12 countries. Lancet Diabetes Endocrinol (in press).

32 Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol 2016; 4: 275–85.

33 Grant P. Management of diabetes in resource-poor settings. Clin Med 2013; 13: 27–31.

34 Tankwanchi ABS, Ozden C, Vermund SH. Physician emigration from sub-Saharan Africa to the United States: analysis of the 2011 AMA physician masterfile. PLoS Med 2013; 10: e1001513.

35 Dhalmi N, Messad N, Nedjai S, et al. Molecular epidemiology of Staphylococcus aureus strains isolated from inpatients with infected diabetic foot ulcers in an Algerian University Hospital. Clin Microbiol Infect 2013; 19: E398–404.

36 Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol 2009; 3: 283–88.

37 Gizaw M, Harries AD, Ade S, et al. Diabetes mellitus in Addis Ababa, Ethiopia: admissions, complications and outcomes in a large referral hospital. Public Health Action 2015; 5: 74–78.

38 Abbas ZG, Archibald LK. Challenges for management of the diabetic foot in Africa: doing more with less. Int Wound J 2007; 4: 305–13.

39 Pendsey S. Clinical profile of diabetic foot in India. Int J Low Extrem Wounds 2010; 9: 180–84.

40 Jeffcoat WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545–51.

41 Wang C, Lv L, Wen X, et al. A clinical analysis of diabetic patients with hand ulcer in a diabetic foot centre. Diabet Med 2010; 27: 848–51.

42 Raimi TH, Adele OO. Tropical diabetes hand syndrome with autoamputation of the digits: case report and review of literature. Pan Afr Med J 2014; 18: 199.

43 Abbas ZG, Archibald LK. Tropical diabetic hand syndrome. Epidemiology, pathogenesis, and management. Am J Clin Dermatol 2005; 6: 21–28.
Diabetes as risk factors for dengue hemorrhagic fever: results of the Burden of Disease Study 2013.

384: 1005–70.

Diminished pro-inflammatory cytokine response (CURES 83).

of lymphatic filariasis among diabetic subjects associated with a derangement of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Pentamidine-induced derangement of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Salim A, Lee VJ, et al. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. PLoS Negl Trop Dis 2012; 6: e1645.

Htun NSN, Odermatt P, Eze IC, Boillot-Blanco N, D’Acquerm P, Probst-Hensch N. Is diabetes a risk factor for a severe clinical presentation of dengue? Review and meta-analysis. PLoS Negl Trop Dis 2015; 9: e0003741.

Figueiredo MAA, Rodrigues LC, Barreto ML, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. PLoS Negl Trop Dis 2010; 4: e699.

Mallhi TH, Khan AH, Adnan AS, Sairif A, Khan YH, Jummaat F. Clinical-laboratory spectrum of dengue viral infection and risk factors associated with dengue hemorrhagic fever: a retrospective study. BMC Infectious Diseases 2015; 15: 199.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.

Pang J, Thein T-L, Leo VS, Iye DC. Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case-control study. BMC Infectious Diseases 2014; 14: 649.

Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg 1984; 78: 252–53.

Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients.

Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. BMC Public Health 2015; 15: 399.
Effects of a mobile phone short message intervention on self-monitoring of blood pressure in an urban population with pre-hypertension: a randomized clinical trial. *J Hypertens* 2013; 31: 1357–64.

117. Dua P, Bhambri S, Pathak S, et al. Impact of a participatory intervention using a mobile phone and community health workers on adherence to diabetes treatment in rural India: a cluster-randomised controlled trial. *Lancet Diabetes Endocrinol* 2016; 4: 490–9.

118. Elahi OA, Alfbaiq I, Alajmi M, et al. Effectiveness of mobile phone intervention on self-management of diabetes in primary care: a cluster-randomized controlled trial. *PloS One* 2013; 8: e60593.

119. Fishbein EB, Boothroyd RI, Coufal MM, et al. Peer support for self-management of diabetes improved outcomes in international settings. *Health Aff (Millwood)* 2012; 31: 110–19.

120. Hoque Z, Katz L, Reis I, Kajdacsy-Balla A, et al. A mobile phone-based intervention for self-care among people with prediabetes. *PLoS One* 2015; 10: e0120242.

121. Khatib N, Khalbous I, El-Hamamsy N, et al. The impact of mobile phone short message intervention on diabetes self-care: a randomized controlled trial in upper-class communities in Jordan. *Lancet Diabetes Endocrinol* 2015; 3: 56–64.

122. Lofgren C, Burtland C, Jaleh P, et al. The impact of a mobile phone intervention on self-care of diabetes patients in an urban area in Bangladesh: a randomized controlled trial. *PLoS One* 2015; 10: e0144770.

123. Lu C, Zhai Y, Song X, et al. A short message service intervention to improve diabetes self-management and glycemic control in rural China: a cluster-randomized controlled trial. *PLoS One* 2014; 9: e99177.

124. Möller HJ, Krüger I, Buchholz H, et al. A mobile phone intervention to improve self-management and glycemic control in patients with type 2 diabetes: a randomized controlled trial. *PLoS One* 2014; 9: e109252.

125. Rehman MA, Zeb A, Khan MI, et al. Effectiveness of a mobile phone intervention on self-care of diabetes patients in urban and rural areas of Pakistan: a cluster-randomized controlled trial. *PLoS One* 2014; 9: e109878.

126. Rahman T, Ahsan M, Ashraf H, et al. Impact of mobile phone-based self-care intervention on glycemic management and self-care activities among type 2 diabetes patients in urban and rural areas of Bangladesh: a cluster-randomized controlled trial. *PLoS One* 2015; 10: e0132511.

127. R盲mг O, Svanberg M, Aziz S, et al. Impact of mobile phone-based self-care and peer support intervention on glycemic control in urban and rural areas of India: a cluster-randomized controlled trial. *PLoS One* 2014; 9: e95685.

128. Safdar S, Khan A, Rehman H, et al. Effectiveness of mobile phone-based intervention on self-care of patients with type 2 diabetes in rural Pakistan: a cluster-randomized controlled trial. *PLoS One* 2013; 8: e76567.